These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A focus on antiarrhythmic properties of ranolazine.
    Author: Vizzardi E, D'Aloia A, Quinzani F, Bonadei I, Rovetta R, Bontempi L, Curnis A, Dei Cas L.
    Journal: J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):353-6. PubMed ID: 22492919.
    Abstract:
    Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the genesis of transmembrane cardiac action potential. It was initially developed as an antianginal agent but was found to additionally exert antiarrhythmic actions, due to its multichannel-blocking properties. In recent years, several studies about the antiarrhythmic properties of ranolazine were conducted, demonstrating the beneficial effects of this drug in both atrial and ventricular arrhythmias, such as atrial fibrillation, ventricular premature beats, ventricular tachycardia, torsades de pointes, and ventricular fibrillation. Our aim is to briefly review the main points of these studies, most more experimental than clinical.
    [Abstract] [Full Text] [Related] [New Search]